Top 10 Contract Development and Manufacturing Organizations 2024

Biopharmaceutical companies are likely to reduce drug discovery in the coming months due to lack of recovery in demand and softening demand trends globally, claimed James C. Foster, CEO of Charles River Laboratories. The CEO shared that second half growth will not materialise as initially expected. However, a survey by Jefferies showed growing demand for certain types of therapies, indicating an optimistic future for CDMOs. The full impact of the BIOSECURE Act on Chinese biotech companies, if it becomes law, is not yet clear.